Zobrazeno 1 - 10
of 150
pro vyhledávání: '"Michael R. Migden"'
Autor:
Guilherme Rabinowits, Michael R. Migden, Todd E. Schlesinger, Robert L. Ferris, Morganna Freeman, Valerie Guild, Shlomo Koyfman, Anna C. Pavlick, Neil Swanson, Gregory T. Wolf, Scott M. Dinehart
Publikováno v:
JID Innovations, Vol 1, Iss 4, Pp 100045- (2021)
Cutaneous squamous cell carcinoma is the second most common skin cancer in the United States. Currently, there is no standardized management approach for patients with cutaneous squamous cell carcinoma who develop metastatic or locally advanced disea
Externí odkaz:
https://doaj.org/article/7bfa396119cd430f85368f3066722ea1
Publikováno v:
Dermatology Practical & Conceptual, Vol 11, Iss S2 (2021)
Cutaneous squamous cell carcinomas (cSCC) represent one of the most diagnosed non-melanoma skin cancers and its incidence is increasing globally. Whereas early stage and low risk cSCC is typically treated with surgery, and in some cases other localiz
Externí odkaz:
https://doaj.org/article/5f50329870c5454eb63b6b30727bf577
Autor:
Carrick Burns, Shelby Kubicki, Quoc-Bao Nguyen, Nader Aboul-Fettouh, Kelly M. Wilmas, Olivia M. Chen, Hung Quoc Doan, Sirunya Silapunt, Michael R. Migden
Publikováno v:
Cancers, Vol 14, Iss 15, p 3653 (2022)
cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. Th
Externí odkaz:
https://doaj.org/article/f72e81260eeb496591a7433bee9b3b2b
Autor:
Olivia M. Chen, Keemberly Kim, Chelsea Steele, Kelly M. Wilmas, Nader Aboul-Fettouh, Carrick Burns, Hung Quoc Doan, Sirunya Silapunt, Michael R. Migden
Publikováno v:
Cancers, Vol 14, Iss 15, p 3720 (2022)
Basal cell carcinoma (BCC), the most common cancer in humans, is a malignant neoplasm of cells derived from the basal layer of the epidermis. Tumor characteristics such as histologic subtype, primary versus recurrent tumor, anatomic location, size, a
Externí odkaz:
https://doaj.org/article/11bfd3d0f3ad403d8e7533dbb66df060
Autor:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and
Externí odkaz:
https://doaj.org/article/369c8eef082e487e8b1ee700e6160944
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 8 (2016)
Treatment of locally advanced basal cell carcinomas (laBCCs) with large, aggressive, destructive, and disfiguring tumors, or metastatic disease is challenging. Dysregulation of the Hedgehog (Hh) signaling pathway has been identified in the vast major
Externí odkaz:
https://doaj.org/article/8f92f0fcbef84c1aab4d36b7094d4d25
Publikováno v:
Acta Dermato-Venereologica, Vol 98, Iss 9, Pp 908-909 (2018)
Externí odkaz:
https://doaj.org/article/240c5e87f2b645869bfcfea3b7fad1ce
Autor:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-1 (2019)
Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:
Externí odkaz:
https://doaj.org/article/c7f86cdcb25043d29d5876749e8c0149
Autor:
Dirk Schadendorf, Thomas K Eigentler, Israel Lowy, Apostolos Papachristos, Samantha Bowyer, Friedegund Meier, Brigitte Dreno, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Axel Hauschild, Brian Stein, Emmanuel Okoye, Jocelyn Booth, Matthew G Fury, Alexander Guminski, Sophie Dalac, Frank Seebach, Marie Beylot-Barry, Suk-Young Yoo, Nicole Basset-Séguin, Sabiha Trabelsi Messai, Victoria Casado Echarren, Anne J Paccaly, Jenny-Hoa Nguyen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Cemiplimab (Libtayo®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who are not candidates for cur
Externí odkaz:
https://doaj.org/article/85c0508e98f2481db714933c819add16
Autor:
Gregory A Daniels, Diwakar Davar, Theresa Medina, Michael R Migden, Trisha M Wise-Draper, Andrew S Poklepovic, Claire Verschraegen, Wanxing Chai-Ho, Jennifer C Tang, Praveen K Bommareddy, Shaheer A Khan, Katy K Tsai, Meenal Kheterpal, Diana Bolotin, Sherrif F Ibrahim, Nathalie C Zeitouni, Chris Tucci, Susan Navia, Laxminarasimha Donthireddy, Jeannie W Hou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2ea6485ff7a9466d90dc9a24c998398d